Hyperglycemia in the Hospital

(modified August 2024)

The information below is provided to help you prevent and treat hyperglycemia in the hospital. Most suggestions are based on expert opinion. Additional information about diabetes care can be found in the 2024 American Diabetes Association (ADA) guidelines at https://diabetesjournals.org/care/issue/47/Supplement_1.

Question

Answer/Pertinent Information

Should non-insulin diabetes medications be discontinued when a patient is admitted to the hospital?

Non-insulin antihyperglycemics may be appropriate.1 Individualize.

  • Sulfonylureas: hold if no or poor nutritional intake, age 75 years or older, CrCl <30 mL/min (<50 mL/min for glyburide), body weight <75 kg, or blood glucose <70 mg/dL.2,3 Some hospitals avoid in all patients due to risk of hypoglycemia and difficulty in titrating.13
  • SGLT-2 inhibitor: due to risk of ketoacidosis, it may be best to hold during most hospitalizations (i.e., hold for acute, severe illness).1,6 A section below provides risk factors and tips for management of SGLT2 inhibitor-associated ketoacidosis.
  • Metformin:
    • hold for eGFR <30 mL/minute/1.73 m2 (severe renal impairment).4,5 Consider holding if eGFR <45 mL/minute/1.73 m2.4,5
    • hold for at least 48 hrs after receipt of iodinated contrast in patients with eGFR 30 to 60 mL/min/1.73 m2.4,5
    • hold if there is laboratory or clinical evidence of liver disease or acute alcohol intoxication.5
    • hold for any condition associated with hypoxemia (e.g., heart failure), dehydration, or sepsis.5
  • Gliptins: consider stopping saxagliptin or alogliptin if heart failure develops.1
  • Pioglitazone: stop in the event of symptomatic heart failure.1
  • GLP-1 agonist: gastrointestinal side effects (nausea and vomiting) could impair recovery (e.g., due to reduced oral intake), cause surgical complications, (e.g., vomiting post-coronary bypass), or be mistaken for acute problems (e.g., ileus).13,20 Avoid.13
  • For patients needing surgery see our chart, Perioperative Management of Diabetes, for guidance on managing non-insulin diabetes medications before and after surgery.
  • If a medication is held, restart it one to two days before discharge.1
  • Consider re-titrating held diabetes meds to improve tolerance, particularly metformin and GLP-1 agonists.

What if the patient is admitted on an insulin pump?

What if the patient is admitted on non-formulary insulin?

What level of hyperglycemia requires treatment in hospitalized patients?
  • Treat symptomatic patients (e.g., polyuria, polydipsia), or those with ketosis.1
  • Experts recommend treating blood glucose persistently ≥180 mg/dL (10 mmol/L).1
  • Once treatment is started, consider a target of 140 to 180 mg/dL (7.8 to 10 mmol/L) for most patients [Evidence level B-1].1,7 However, the goal must be individualized.1
    • A goal of 100 to 180 mg/dL (5.6 to 10 mmol/L) for noncritically ill patients with “new” hyperglycemia, or for patients previously diagnosed with diabetes, or perioperatively, is recommended.1
    • A goal of 110 to <140 mg/dL (6.1 to <7.8 mmol/L) may be appropriate (e.g., critically ill surgical patients) if hypoglycemia can be avoided.1
    • A goal >180 mg/dL (10 mmol/L) may be appropriate for patients with limited life expectancy, the elderly, or for patients with significant comorbidities.1,13

Which insulin or insulin regimen should be used?
  • Insulin infusion is preferred for critical care patients.1
    • Adjust infusion rate per protocol.1
    • Switch patients from insulin infusions to subcutaneous insulin by starting basal insulin two hours before stopping the insulin drip.1 The dose can be calculated based on the insulin infusion rate administered over a six-to eight-hour period when blood glucose targets were met.1
  • In non-ICU patients, start with a regimen containing basal insulin, such as 0.15 to 0.25 units/kg/day.8,10
    • For most patients with adequate nutritional intake, add prandial (bolus) and correction (sliding scale) doses, especially for those who use this regimen at home, or who take more than two antidiabetic meds at home.1,13
    • Check a premeal fingerstick before administering nutritional insulin doses.1,9 Consider waiting until after the meal to give insulin if the patient may eat poorly.1,9
  • If admission blood glucose is under 180 mg/dL (10 mmol/L), consider starting with sliding scale insulin as an alternative to basal regimens in non-ICU patients [Evidence level B-3].11-13
    • May be most appropriate for certain patients, such as those who are insulin-naïve or at higher risk for hypoglycemia (e.g., elderly, kidney failure).13
    • Add basal insulin if hyperglycemia persists for 24 to 48 hours.11
  • Patients receiving bolus or continuous enteral nutrition will need basal, nutritional, and correction doses.1 Patients receiving parenteral nutrition or not eating will need basal plus correction doses.1 Check fingersticks every six hours and give a correction dose regular insulin if needed.1
    • Before each bolus feeding, consider a dose of 1 unit of subcutaneous regular or rapid-acting insulin per 10 to 15 g of carbohydrates.1
    • For patients on parenteral nutrition, consider adding regular insulin to the solution starting with a dose of 1 unit per 10 g of dextrose, especially if >20 units of correctional insulin is needed per 24 hours. Adjust daily.1
  • Avoid use of premixed insulin in the hospital due to hypoglycemia risk.1

How are hyperglycemic crises treated?
  • Follow your institution’s protocols.21 Example: https://www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-dka-or-hhs-web-algorithm.pdf.
  • For DKA and HHS, treatment goals are similar and include correction of:21
    • dehydration: initially corrected with NS or LR (LR might correct DKA faster, with lower risk of hyperchloremic metabolic acidosis).19,21 After volume resuscitation, the fluid can be switched to ½ NS (especially if osmolality is not falling in HHS despite correct insulin dosing), unless corrected sodium (see below) is low or plasma osmolality is falling >3 mmol/kg/hr).14,18,21 Once glucose reaches ~250 mg/L (13.9 mmol/L), switch to a dextrose-containing fluid to prevent hypoglycemia.21
    • electrolyte imbalance:
      • potassium: insulin deficiency and metabolic acidosis cause potassium to shift extracellularly, so potassium may appear normal or high even if total body stores are depleted.21 Potassium replacement is needed unless potassium is >5 mEq (mmol)/L.21 Reassess potassium every two hours and switch to a potassium-containing fluid when potassium is <5 mEq (mmol)/L.21 Insulin administration causes potassium to shift, so in hypokalemic patients insulin administration should be delayed until potassium replacement has increased serum potassium to ≥3.5 mEq (mmol)/L.21
      • sodium: hyperglycemia causes water to shift out of the cells, causing a dilutional hyponatremia.14 “Correct” serum sodium for glucose level (https://www.mdcalc.com/sodium-correction-hyperglycemia).
    • hyperglycemia: traditionally corrected with continuous intravenous insulin infusion (plus, the patient’s outpatient subcutaneous basal insulin, if applicable).21
      • Evidence is accumulating that using subcutaneous insulin instead of an intravenous infusion for DKA in nonpregnant adults not sick enough to require ICU care reduces ICU admission without increased risk of hypoglycemia.15
        • Patients who are alert and appropriate for regular room or observation bed care (e.g., pH >7.25 to <7.3 or serum bicarbonate >15 mmol/L, beta-hydroxybutryate <6 mmol/L) may be candidates.21
        • Generally avoid subcutaneous protocols if insulin absorption or response may be unpredictable (e.g., severe obesity, severe kidney impairment), or the patient is unstable (e.g., not alert, potassium <3.3 mEq (mmol)/L, serum bicarbonate <10 mEq (mmol)/L, hypotensive despite 1 L of IV fluid).15,17
        • Consider a subcutaneous protocol that starts with rapid-acting insulin 0.1 to 0.3 units/kg x 1, then 0.1 units/kg every hour or 0.2 units/kg every two hours.16,21  Once glucose reaches 250 mg/dL (13.9 mmol/L), step down to 0.1 units/kg every two hours.21
    • hyperosmolality (HHS):
      • Avoid dropping osmolality too quickly due to the risk of osmotic demyelination syndrome. Use normal saline to keep the fall in osmolality to 3 to 8 mOsm/kg/hr.21
      • Considered resolved when serum osmolality is <300 mOsm/kg, glucose is <250 mg/dL (13.9 mmol/L), urine output is >0.5 ml/kg/h, and cognition has improved.21
    • ketonemia (DKA):
      • Maintain intensive insulin until DKA resolves (e.g., plasma ketones <0.6 mmol/L, plus venous pH ≥7.3 or serum bicarbonate ≥18 mmol/L).21 Use a dextrose-containing fluid if needed to prevent hypoglycemia.21
      • Do not use sodium bicarbonate for DKA except for life-threatening acidosis (e.g., pH <7).21
  • Monitoring parameters include vitals, input/output, blood beta-hydroxybutyrate, glucose (every one to two hours), and other labs (e.g., electrolytes, venous pH, osmolality, kidney function) every two to four hours until stable.21
What is euglycemic DKA? 
  • These patients meet DKA criteria (blood ketones ≥3 mmol/L and serum bicarbonate <18 mEq/L), but have a glucose <200 mg/dL (11.1 mmol/L).21
  • In addition to SGLT2 inhibitors (most common cause), euglycemic ketoacidosis may be caused by pregnancy, insulin injection, food restriction, alcohol, or liver failure.21
    • Also see information about ketoacidosis caused by SGLT2 inhibitors, below.
  • Because glucose is near-normal, it is important to start a dextrose-containing solution with the insulin infusion to prevent hypoglycemia.21

How do you manage ketoacidos is caused by an SGLT2 inhibitor?
  • Prevention
    • Be alert for risk factors: fasting or reduced caloric intake due to illness or surgery, low carbohydrate diet, dehydration, infection, hemodynamic instability, pancreatic disorders, type 1 diabetes, alcohol use, reduction of insulin dose, or history of diabetic ketoacidosis.6,22
      • For patients using insulin at home, ensure adequate insulin dosage.22 Try not to stop insulin altogether; reduce dose cautiously, and avoid sliding scale insulin alone.22
  • Identification
    • In current or recent users of an SGLT2 inhibitor, watch for ketoacidosis symptoms (e.g., nausea, vomiting, abdominal pain, lethargy, dyspnea).6,25
    • Consider checking serum bicarbonate and anion gap daily (e.g., basic metabolic panel).22
    • Laboratory findings suggestive of SGLT2 inhibitor acidosis include metabolic acidosis with an elevated anion gap and low serum bicarbonate.6 Blood glucose is typically <250 mg/dL (13.9 mmol/L).6 Check arterial blood gas and serum ketones to confirm ketoacidosis.22 Urine ketones may be undetectable.22
  • Treatment
    • Stop SGLT2 inhibitor if still taking.6
    • Treat ketoacidosis as usual, but with some caveats; update your protocol to include distinctions for SGLT2-associated ketoacidosis,24,26 Start IV insulin even with blood glucose <250 mg/dL (13.9 mmol/L), plus an IV dextrose-containing solution to keep glucose 150 to 200 mg/dL (with normal saline for fluid resuscitation).6,21,24,26 Suggested initial insulin dose is 0.02 to 0.05 units/kg/hour.24 Titrate insulin to serum ketones, not blood glucose.23 Patients may require insulin infusion several days, and high doses may be required (e.g., 10 units/hour).23
    • Once the patient stabilizes (e.g., resolution of ketoacidosis [e.g., two of: serum bicarbonate ≥15 mmol/L, anion gap ≤12 mmol/L, venous pH >7.3], tolerating oral diet), transition to subcutaneous insulin (e.g., previous home regimen).22,24 Check a basic metabolic panel in about four hours to confirm resolution.22
    • Insulin naïve patients may need to continue insulin at home if they are insulin deficient and therefore at risk of repeat ketosis.22
    • With shared decision-making, consider restarting the SGLT2 inhibitor if the patient has an indication for it other than diabetes (i.e., heart failure or kidney disease) and an identifiable trigger for ketoacidosis.22 Educate the patient about prevention (e.g., sick-day management, adequate hydration, responsible alcohol use, symptom recognition), and ensure the episode is documented for future admissions.22

Will patients who need insulin in the hospital need it upon discharge?
  • An A1c of 6.5 % or higher on admission suggests that the patient had diabetes preadmission.1
  • Consider insulin as a component if A1c is >9% to 10%.1
  • Consider NPH over newer basal insulin analogues for lower cost, especially in those without hypoglycemia history.1
  • Schedule follow-up within one month or earlier, such as within 1 to 2 weeks for suboptimal glucose control at discharge or if diabetes regimens are changed.1

Abbreviations: DKA = diabetic ketoacidosis; HHS = hyperglycemic hyperosmolar state; ICU = intensive care unit; IV = intravenous; LR = lactated Ringer’s; NS = normal saline.

References

  1. Standards of medical care in diabetes – 2024. Diabetes Care 2024;47(Suppl 1):S1-308.
  2. Milligan PE, Bocox MC, Pratt E, et al. Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system. Am J Health Syst Pharm. 2015 Oct 1;72(19):1631-41.
  3. Minnesota Hospital Association. Hypoglycemic agent adverse drug event gap analysis. Component of the medication safety road map. 2012. http://www.mnhospitals.org/Portals/0/Documents/ptsafety/ade/Medication-Safety-Gap-Analysis-Hypoglycemic.pdf. (Accessed September 13, 2023).
  4. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. November 14, 2017. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. (Accessed September 13, 2023).
  5. Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2023. http://www.clinicalkey.com. (Accessed September 13, 2023).
  6. FDA drug safety communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Revised March 15, 2022. (Accessed September 15, 2023).
  7. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.
  8. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-188.
  9. ISMP. Adverse glycemic events and critical emergencies. December 1, 2021. https://home.ecri.org/blogs/ismp-resources. (Accessed September 14, 2023).
  10. Migdal AL, Idrees T, Umpierrez GE. Selecting Insulin Regimens for the Management of Non-ICU Patients With Type 2 Diabetes. J Endocr Soc. 2021 Aug 18;5(10):bvab134.
  11. Migdal AL, Fortin-Leung C, Pasquel F, et al. Inpatient Glycemic Control With Sliding Scale Insulin in Noncritical Patients With Type 2 Diabetes: Who Can Slide? J Hosp Med. 2021 Aug;16(8):462-468.
  12. Sadhu AR, Patham B, Vadhariya A, et al. Outcomes of "Real-World" Insulin Strategies in the Management of Hospital Hyperglycemia. J Endocr Soc. 2021 Jun 16;5(8):bvab101.
  13. Pasquel FJ, Umpierrez GE. Web Exclusive. Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital. Ann Intern Med. 2021 Aug;174(8):HO2-HO4.
  14. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606.
  15. Rao P, Jiang SF, Kipnis P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022 Apr 1;5(4):e226417.
  16. Ibarra F Jr, Bae R, Haghighat B. Review of Subcutaneous Insulin Regimens in the Management of Diabetic Ketoacidosis in Adults and Pediatrics. Ann Pharmacother. 2024 Jul 25:10600280241263357.
  17. Agarwal S, Crandall J, Tomer Y. Albert Einstein College of Medicine. Montefiore subcutaneous insulin DKA protocol. 3.0. May 22, 2020. https://professional.diabetes.org/sites/default/files/media/ada-montefiore_dka_protcol_version_3.0_5_22_20.pdf (Accessed September 14, 2023).
  18. Diabetes Canada Clinical Practice Guidelines Expert Committee; Goguen J, Gilbert J. Hyperglycemic Emergencies in Adults. Can J Diabetes. 2018 Apr;42 Suppl 1:S109-S114.
  19. Self WH, Evans CS, Jenkins CA, et al. Pragmatic Critical Care Research Group. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis: A Subgroup Analysis of Cluster Randomized Clinical Trials. JAMA Netw Open. 2020 Nov 2;3(11):e2024596.
  20. Das S< Green JB. Should SGLT2 inhibitors and GLP-1 receptor agonists be initiated in the hospital? https://www.ccjm.org/page/ada-2021/sglt2-glp1-initiated. (Accessed September 14, 2023).
  21. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024 Jun 22.
  22. Selwyn J, Pichardo-Lowden AR. Managing hospitalized patients taking SGLT2 inhibitors: reducing the risk of euglycemic diabetic ketoacidosis. Diabetology (Basel). 2023;4:86-92.
  23. Almazrouei R, Alkindi F, Alshamsi A, et al. Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review. Oman Med J. 2022 May 31;37(3):e373.
  24. Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med. 2019 Sep 5;12(1):27.
  25. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022 Sep;28(9):884-888.
  26. Lehenbauer KS, Tsangaris A, Bart BA, et al. Euglycemic DKA in the setting of SGLT2 inhibitor therapy demands cardiologists’ awareness and revision of standardized treatment protocols [abstract]. J Am Coll Cardiol 2022 Mar, 79 (9_Supplement): 2871.

Cite this document as follows: Clinical Resource, Hyperglycemia in the Hospital. Pharmacist’s Letter/Pharmacy Technician’s Letter/Prescriber Insights. October 2023. [391006]



Related Articles